• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 12th November 2013

Assessing Use of the EQ-VAS in the NHS PROMs Programme

This research addresses two critical issues about the use of the EQ-VAS. A paper recently published in Quality of Life Research by OHE’s Nancy Devlin and Yan Feng with David Parkin, King’s College, London, describes research on the use of…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
The visual analogue scale in the EQ-5D: the EQ VAS

This research addresses two critical issues about the use of the EQ-VAS.

A paper recently published in Quality of Life Research by OHE’s Nancy Devlin and Yan Feng with David Parkin, King’s College, London, describes research on the use of the EQ-VAS in the NHS Patient Reported Outcome Measures (PROMs) programme.

The visual analogue scale in the EQ-5D: the EQ VAS

A paper recently published in Quality of Life Research by OHE’s Nancy Devlin and Yan Feng with David Parkin, King’s College, London, describes research on the use of the EQ-VAS in the NHS Patient Reported Outcome Measures (PROMs) programme[1]. Introduced in April 2009, PROMs data now are used in a range of decision making contexts.

The EQ-5D, used to collect the PROMs data, has two parts. The first, the EQ-5D profile, asks patients to classify their health based on self-assessed levels of problems (“no”, “some”, “extreme”). The second is the EQ-VAS, which asks patients to indicate their overall health on a vertical visual analogue scale, ranging from “worst possible” to “best possible” health. Historically, the EQ-VAS was a warm-up exercise for VAS valuations of EQ-5D, but it has evolved into an integral part of the measure.

This paper focuses on two concerns about the EQ-VAS: (1) difficulties with the data because patients may fail to respond to it as the instructions require and (2) substantial differences between patient responses on the EQ-VAS versus the EQ-5D profile and condition-specific instruments. According to the authors, these issues raise fundamental questions about the role and use of EQ-VAS in the EQ-5D instrument.

In particular, the paper analyses:

  1. Differences in how patients complete the EQ-VAS and how their characteristics affect this
  2. How coding the data take account of these differences and what effect this may have on data interpretation and analysis
  3. How the EQ-VAS, the EQ-5D profile and other summary score data relate to one another in the NHS PROMs programme.

The authors’ findings suggest ways for improving EQ-VAS by improving both data collection and coding procedures. They note, for example, that although 95% of patients completed the EQ-VAS in an unambiguous way, fewer than 50% completed it in the way that the instructions intend. Moreover, the guidance provided by the EuroQol Group on coding the imperfect responses is insufficient in ways that may negatively affect data use. “All of these issues,” they note, “could be addressed by providing improved guidance on coding EQ-VAS data or revisiting the instructions for the EQ-VAS”.

The third set of analyses address whether and how patient-reported outcomes vary using EQ-VAS versus EQ-5D or condition-specific instruments. The authors note that “Concern had emerged from the NHS PROMs programme that the EQ-VAS was not adequately reflecting the health gain for patients resulting from surgery, and was therefore a less useful and appropriate measure of health change than the EQ-5D profile or condition specific instruments.” Their findings suggest that this is not the case; the relationship between the EQ-VAS and the EQ-5D profile are predictable and consistent. Moreover, some of the differences between the two are attributable to the characteristics of the particular weightings within the EQ-5D index.

The research does show clear differences between the EQ-VAS and index-weighted EQ-5D and condition-specific profiles. Presumably, patients are freer to consider all components of “health” using the VAS than they are when restricted to “tick boxes” with the EQ-5D profile. “In essence,” the authors state,”the EQ-VAS is measuring a broader underlying construct than the EQ-5D profile or the condition-specific instruments. This does not mean that the data it produces are less meaningful or useful. Indeed, in applications where the patients’ view of their overall health is the measurement goal, the EQ-VAS is prima facie more appropriate than the use of EQ-5D profile data weighted by general public preferences.”

For additional information, please contact Nancy Devlin.

For an oveview of OHE’s extensive activities and research on the EQ-5D and PROMS, click here. For a presentation by Prof Devlin summarising the EQ-5D and it uses, click here.


[1]  Feng, Y., Parkin, D. and Devlin, N.J. (2013) Assessing the performance of the EQ-VAS in the NHS PROMs Programme. Quality of Life Research. Epub ahead of print. 1 October.   

An earlier version of this article appeared as OHE Research Paper 12/01, which may be downloaded here.
  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!